Quotes 5-day view Delayed Nasdaq
01/14/2021
01/15/2021
01/19/2021
01/20/2021
01/21/2021
Date
2.69(c)
2.65(c)
2.52(c)
2.77(c)
2.72
Last
368 258
513 258
401 704
1 178 350
201 362
Volume
+1.51%
-1.49%
-4.91%
+9.92%
-1.81%
Change
Sales 2018
1,67 M
-
-
Net income 2018
-10,8 M
-
-
Net cash position 2018
5,46 M
-
-
P/E ratio 2018
-1,22x
Yield 2018
-
Sales 2019
1,58 M
-
-
Net income 2019
-3,89 M
-
-
Net cash position 2019
9,68 M
-
-
P/E ratio 2019
-0,50x
Yield 2019
-
Capitalization
24,5 M
24,5 M
-
EV / Sales 2018
5,19x
EV / Sales 2019
-3,83x
Nbr of Employees
12
Free-Float
84,1%
Akers Biosciences, Inc. develops, manufactures, and supplies point-of-care screening and testing products designed to bring health-related information directly to the patient or clinician. The Company’s product offerings focus on delivering diagnostic assistance in a variety of healthcare fields/specialties, including diagnostic rapid manual point-of-care tests for the detection of allergic reactions to Heparin...
All news about AKERS BIOSCIENCES, INC.
2020 AKERS BIOSCIENCES INVESTOR ALERT BY : Kahn Swick & Foti, LLC Investigates Merge..BU
2020 AKERS BIOSCIENCES : ' Proposed Merger Partner MyMD Pharmaceuticals Announces Iss..BU
2020 AKERS BIOSCIENCES, INC. : Change in Directors or Principal Officers (form 8-K)AQ
2020 AKERS BIOSCIENCES, INC. : Other Events, Financial Statements and Exhibits (form ..AQ
2020 AKERS BIOSCIENCES, INC. : Other Events, Financial Statements and Exhibits (form ..AQ
2020 REMINDER : Akers Biosciences Schedules Conference Call to Discuss Merger with My..BU
2020 AKERS BIOSCIENCES INVESTOR ALERT BY : Kahn Swick & Foti, LLC Investigates Merge..BU
2020 AKERS BIOSCIENCES : Management's Discussion and Analysis of Financial Condition ..AQ
2020 AKERS BIOSCIENCES, INC. : Other Events (form 8-K)AQ
2020 AKERS BIOSCIENCES : Entry into a Material Definitive Agreement, Unregistered Sal..AQ
2020 AKERS BIOSCIENCES, INC. : Entry into a Material Definitive Agreement, Unregister..AQ
2020 AKERS MERGER INVESTIGATION : Halper Sadeh LLP Announces Investigation Into Wheth..BU
2020 Akers Biosciences, MyMD Pharmaceuticals Ink Merger Agreement MT
2020 AKERS BIOSCIENCES : and MyMD Pharmaceuticals Sign Definitive Merger AgreementBU
2020 AKERS BIOSCIENCES, INC. : Change in Directors or Principal Officers (form 8-K)AQ
News in other languages on AKERS BIOSCIENCES, INC.
- No features available -
Chart AKERS BIOSCIENCES, INC.
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends AKERS BIOSCIENCES, INC.
Short Term Mid-Term Long Term Trends Bullish Bearish Bearish
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.